🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Aflibercept in Recurrent or Persistent CNV

Recruitingn/aAges 50 Years - anyAllMedical University of Vienna
NCT02669953 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Age-related macular degeneration (AMD) and diabetic retinopathy are among the most common disorders causing visual disability in elderly people. AMD leads to dysfunction and loss of photoreceptors in the central retina. Neovascular AMD (nAMD) affects visual function early in the disease process. The purpose of the study is to evaluate the effect of switching from ranibizumab therapy to the current routine therapy using aflibercept in eyes with treatment naive, recurrent or persistent nAMD, treatment naive diabetic retinopathy and pretreated diabetic retinopathy. 20 patients with recurrent or persistent nAMD, previously treated with intravitreal ranibizumab for up to one year will be included in this trial. Patients will be examined in monthly intervals over 12 months follow-up. Examinations carried out will include: Best-corrected visual acuity (BCVA) using ETDRS charts at 4m distance

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Adults ≥ 50 years * Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year * BCVA \>= 20/400 in the study eye using ETDRS * Willingness and ability to comply with regular visits * Signed informed consent Exclusion Criteria: * Any surgical treatment of the eye within 3 months prior to baseline in the study eye * History of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation) * Aphakia or absence of the posterior capsule (excluding YAG-capsulotomy) in the study eye * Retinal pigment epithelial tear involving the macula in the study eye
💊

What it tests

  • Aflibercept
📍

Where

1 site
Medical University of Vienna
Vienna, Austria
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy